RAVLT could help to identify those patients with SMC who would progress to DAT over a few years, and also to differentiate between the preclinical phase of Alzheimer's disease, mild cognitive impairment and normal aging. A score of zero at the delayed recall test or a percentage of forgetting > or =75% in patients with SMC is suggestive of probable DAT in the future.

Patients with dementia of Alzheimer’s type (DAT) show severe impairment in recognizing famous people. The aim of the current study was to investigate if this well-known memory impairment of famous faces is already present in the preclinical phase of DAT and if the famous faces test can help to differentiate patients with mild cognitive impairment (MCI) who progress to dementia and those who do not. We compared baseline performance in a task of famous face identification in a sample of 116 patients with subjective memory complaints classified in three groups: 17 participants with no evidence of cognitive impairment; 26 patients with MCI who had not developed dementia, and 27 patients with MCI who had developed probable DAT 2 years later. The remaining patients were excluded because they abandoned or did not meet the applied restrictive criteria for DAT, MCI or control. MCI patients who were diagnosed 2 years later with DAT performed significantly worse in the preclinical phase than MCI and control participants (p < 0.004). Patients with MCI but not DAT obtained intermediate results between control subjects and MCI patients who develop Alzheimer’s disease. A neuropsychological task of semantic knowledge of famous people may be useful in the early diagnosis of Alzheimer’s disease.

The existing studies about the utility of P300 latency for diagnostically classifying patients in preclinical stages of dementia are cross-sectional rather than longitudinal in design, and their results are inconclusive. The authors investigated the P300 value in a series of patients with subjective memory complaints using a prospective design. The study was performed in a consecutive series of 116 outpatients with subjective memory complaints as the predominant symptom. P300 (auditory oddball task) was performed immediately after the first clinical evaluation, and at 12 and 24 months. Final cognitive syndrome diagnosis (mean follow-up period, 27.7 months) was then made by a neurologist who was blinded to the neurophysiologic results. Diagnosis at the end of follow-up was 30 cases of normal cognition, 30 cases of mild cognitive impairment, 28 cases of dementia of Alzheimer's type (DAT), five cases of vascular dementia, and one case of frontotemporal dementia; 22 patients were lost to follow-up. P300 latency was significantly higher for the DAT group (analysis of variance: P=0.023) throughout the study. The diagnostic value of P300 latency at baseline examination for DAT had a sensitivity of 52.9% and a specificity of 76.9%; the odds ratio was 3.75 (95% confidence interval, 1.23-11.41). Findings from the present study suggest that assessment of evoked related potentials may contribute to the early detection of DAT.

No abstract

To investigate the association between APOE-Ε4 allele and memory phenotype in the preclinical stage of Alzheimer’s disease (AD). We compared an extensive preclinical memory profile at the baseline evaluation of 2 AD genotype groups: APOE-Ε4 allele carriers and patients with APOE-Ε3 homozygosity. Baseline memory performance was carried out at least 2 years (interval of 27.7 ± 4 months) before AD diagnosis was established, and analysis included different modalities of working memory (visuoperceptive, visuospatial, digit span and processing speed), of declarative memory (recent, verbal learning, prospective and semantic) and of nondeclarative memory (procedural, incidental and priming). We found no significant differences: memory performance was similar in both genotype groups. The presence of the APOE-Ε4 allele does not seem to be sufficient to cause a distinctive preclinical memory phenotype in AD patients.